ArticleRenal failure2025
Employing urinary biomarkers in predicting renal recovery three months after in-hospital acute kidney injury.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent advances in the clinical significance and physiological functions of uromodulin: a narrative review.BMC nephrology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRenal recovery after acute kidney injury (AKI) significantly improves outcomes. This cohort study explored the efficacy of six urinary biomarkers and the spot urine creatinine-to-osmolality ratio (sUCr/Osm) in predicting renal recovery 3 months after in-hospital AKI.
methodsData from the Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury study, involving 744 patients with in-hospital AKI, were analyzed. The urinary biomarker with the highest area under the receiver operating characteristic curve (AUC) was selected as the representative for comparison. Renal recovery was defined as an absolute increase of <26.5 μmol/L or a relative elevation of <20% from the baseline serum creatinine (SCr) level at three months postdiagnosis.
resultsAmong the 744 patients, 85.6% achieved renal recovery. Uromodulin demonstrated a greater AUC of 0.580 (95% CI: 0.518-0.641) than the other five biomarkers did. With a cutoff of 1,360 ng/mL, uromodulin sensitivity was 0.774 (95% CI: 0.741-0.806). The sUCr/Osm test exhibited high sensitivity (0.881; 95% CI: 0.856-0.906) with a cutoff of 8.84 (sUCr/Osm8.84) and high specificity (0.785; 95% CI: 0.707-0.863) with a cutoff of 21.22 (sUCr/Osm21.22). The positive predictive values of the three methods were approximately 0.880. The performance of these tests in predicting renal recovery based on both criteria in 298 patients with chronic kidney disease was also comparable.
conclusionUrinary biomarkers, especially uromodulin, and the sUCr/Osm test may be effective in predicting renal recovery three months after in-hospital AKI. The sUCr/Osm test may offer a more accessible approach for routine use, with sUCr/Osm8.84 demonstrating high sensitivity for screening and sUCr/Osm21.22 exhibiting high specificity for further discrimination.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.